Practice Essentials

Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma
Pharmacotherapeutic Considerations for New Drug Regimens in Comorbid Patients with Multiple Myeloma
CME, CPE
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA
Release Date: July 19, 2017
Expiration Date: July 19, 2018

The addition of new lenalidomide- and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. There are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In this activity, Dr. Harvey will discuss hepatic and renal dysfunction, diabetes, and cardiovascular dysfunction, all of which can impact pharmacy-related decisions such as dose-modification, treatment interruption, or administration of concomitant medications.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
Begin, Earn CreditView Only, No Credit
 
Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Managing Major Adverse Events in Relapsed/Refractory Multiple Myeloma
CME, CPE
Ajay K. Nooka, MD, MPH, FACP
Release Date: May 17, 2017
Expiration Date: May 17, 2018

Treatment-related adverse events (AEs) can have a significant impact on patients with multiple myeloma, including poorer outcomes, premature discontinuation of therapy, and reduced quality of life. There are a number of characteristic major AEs associated with treatment options for patients with relapsed/refractory disease, which must be monitored for and managed appropriately. In this activity, participants will learn about the major AEs associated with emerging and standard of care agents for relapsed/refractory multiple myeloma (RRMM), including clinical pearls for patient monitoring and toxicity mitigation strategies that can be implemented in clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Testing Strategies throughout the Myeloma Disease Lifecycle
Testing Strategies throughout the Myeloma Disease Lifecycle
CME, CPE
Philip L. McCarthy, MD
Release Date: April 26, 2017
Expiration Date: April 26, 2018

The diagnosis, prognostication, and assessment of patients with myeloma spans a gamut of testing strategies, including identification of key abnormal laboratory values, cytogenetic aberrations, and evidence of radiographic disease. In addition to new IMWG diagnosis criteria and the Revised ISS, various clinical strategies have been developed to identify high-risk patients and guide treatment decisions. In this activity, Dr. McCarthy will discuss presenting symptomatology and diagnostic recommendations for patients suspected of having multiple myeloma, including prognostic tests that should be considered as part of the initial workup. The activity will conclude with a discussion of patients who relapsed from complete remission, as well as those who developed frank disease progression.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
The Predictive Potential of Genomics in Multiple Myeloma
The Predictive Potential of Genomics in Multiple Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: March 22, 2017
Expiration Date: March 22, 2018

Predictive markers have the potential to guide treatment selection and personalize therapeutic strategies for patients with multiple myeloma. Cytogenetic abnormalities, including del(17p), t(4;14) and t(14;16), are hallmarks of high-risk disease, but these genomic aberrations have also been implicated as potential predictive markers. Other genomic predictive markers are under investigation, such as t(14;20) and the SKY92 signature identified through gene expression profiling. In this activity, participants will learn about various genomic predictive markers under investigation and their potential to guide treatment decisions for patients with multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Practical Considerations in Multiple Myeloma: Optimizing Therapy with New Proteasome Inhibitors
Practical Considerations in Multiple Myeloma: Optimizing Therapy with New Proteasome Inhibitors
CME, CPE
R. Donald Harvey III, PharmD, BCOP, FCCP, FHOPA
Release Date: November 28, 2016
Expiration Date: November 28, 2017

This activity will focus on how new proteasome inhibitors may be safely and effectively incorporated into clinical practice for the management of patients with multiple myeloma. Practical aspects of optimizing therapy with these agents will be addressed, including patient selection, compliance, and side-effect management, as well as guidelines on differentiating between available proteasome inhibitors in clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Celgene Corporation, and Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
Gene Expression Profiling in Multiple Myeloma: The Basics
Gene Expression Profiling in Multiple Myeloma: The Basics
CME, CPE
Rafael Fonseca, MD
Release Date: November 10, 2016
Expiration Date: November 10, 2017

Gene expression profiling (GEP) has the potential to further individualize risk assessment, prognostication, and treatment selection for patients with multiple myeloma. In this activity, Dr. Rafael Fonseca will provide an overview of GEP including advantages and disadvantages, currently available tests, and differences between GEP and traditional methods for establishing molecular profiles, such as fluorescence in situ hybridization (FISH) and whole exome sequencing. In addition, Dr. Fonseca will describe the two major genetic classification systems in multiple myeloma: translocation and cyclin D (TC) and University of Arkansas for Medical Sciences (UAMS).

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No Credit
 
Gene Expression Profiling in Multiple Myeloma: Implications for Practice
Gene Expression Profiling in Multiple Myeloma: Implications for Practice
CME, CPE
Rafael Fonseca, MD
Release Date: November 10, 2016
Expiration Date: November 10, 2017

Advances in gene expression profiling (GEP) for patients with multiple myeloma have identified gene signatures that aid in risk assessment, disease prognostication, and possible treatment selection. In this activity, Dr. Rafael Fonseca will explain the utility of GEP for risk stratification and disease prognostication, as well as the role of GEP among traditional risk assessment tools, such as the revised International Staging System (R-ISS). In addition, Dr. Fonseca will describe the potential for treatment selection and individualized therapy based on specific investigational gene signatures.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No Credit
 
Relapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents
Relapsed/Refractory Multiple Myeloma: Standard of Care Among Emerging Agents
CME, CPE
Adam D. Cohen, MD
Release Date: October 19, 2016
Expiration Date: October 19, 2017

The multitude of novel agents and new drug regimens approved in relapsed/refractory multiple myeloma (RRMM) has made a major impact on treatment paradigms and clinical practice recommendations. In this activity, Dr. Adam D. Cohen, the Director of Myeloma Immunotherapy and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, will describe the current standard of care in RRMM, taking into account new therapies and updates to disease management guidelines, as well as future outlooks on the treatment landscape.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No Credit
 
Performance Status Adaptive Therapy in Multiple Myeloma
Performance Status Adaptive Therapy in Multiple Myeloma
CME, CPE
Joshua Richter, MD
Release Date: August 05, 2016
Expiration Date: August 05, 2017

This activity will summarize the emerging approach of performance status adaptive therapy in multiple myeloma, and will focus on the key patient and disease characteristics that indicate which regimen(s) and dose adjustments may be the most appropriate for an individual myeloma patient.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Relapsed/Refractory Multiple Myeloma: Navigating Treatment Pathways
Relapsed/Refractory Multiple Myeloma: Navigating Treatment Pathways
CME, CPE
Jatin J. Shah, MD
Release Date: July 15, 2016
Expiration Date: July 15, 2017

The management of multiple myeloma is rapidly changing due to the introduction of new therapies into the treatment landscape, including next-generation immunomodulatory agents and proteasome inhibitors, as well as immunotherapy and a histone deacetylase inhibitor. This activity will explain the various treatment pathways that exist for patients with relapsed or refractory multiple myeloma, of which clinical relapse can be defined as one or more of the following: development of new soft tissue plasmacytomas or bone lesions, definite increase in the size of existing plasmacytomas or bone lesions, hypercalcemia (>11.5 mg/dL), decrease in hemoglobin of >2 g/dL and/or a rise in serum creatinine by ≥2 mg/dL. In addition, the activity will discuss key takeaways from the pivotal clinical trials for these novel agents, providing clinicians with the data and rationales for selecting the most appropriate therapy for patients in the relapsed or refractory setting

To download the accompanying e-Transcript for reference purposes only click here

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation, and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit
 
Proteasome Inhibitor plus IMiD or HDAC Inhibitor Regimens in R/R Myeloma Management
Proteasome Inhibitor plus IMiD or HDAC Inhibitor Regimens in R/R Myeloma Management
CME, CPE
Antonio Palumbo, MD
Release Date: July 13, 2016
Expiration Date: July 13, 2017

The treatment landscape for relapsed/refractory multiple myeloma (MM) is evolving with the availability of new therapies, including the third-generation immunomodulatory drug pomalidomide, and the histone deacetylase inhibitor panobinostat. These new therapies present a challenge to community oncologists who must determine how to incorporate these drugs into clinical practice. Dr. Antonio Palumbo, Associate Professor of Clinical Hematology and Director of the Myeloma Program at the University of Torino, provides an overview of the most recent data supporting the use of pomalidomide and panobinostat in proteasome inhibitor-containing regimens, and shares clinical expertise in managing patients with relapsed/refractory MM who receive these therapies..

To download the accompanying e-Transcript for reference purposes only click here

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Amgen Inc.
View Only, CE ExpiredView Only, No Credit
 
Integrating Proteasome Plus Second-Generation IMiD-Based Regimens into Relapsed/Refractory Multiple Myeloma Management
Integrating Proteasome Plus Second-Generation IMiD-Based Regimens into Relapsed/Refractory Multiple Myeloma Management
CME, CPE
Antonio Palumbo, MD
Release Date: May 31, 2016
Expiration Date: May 31, 2017

The treatment of patients with relapsed/refractory multiple myeloma includes multiple therapeutic options, including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs), providing a variety of synergistic drug combinations and possible regimen sequences when prior treatment becomes ineffective. Given the availability of the second-generation PI carfilzomib, practitioners are challenged with understanding how to appropriately integrate bortezomib- and carfilzomib-containing two- and three-drug regimens into clinical practice, while individualizing treatment and managing adverse events. Join Dr. Antonio Palumbo, Associate Professor of Clinical Hematology and Director of the Myeloma Unit at the University of Torino, as he reviews the latest data on utilizing PI-containing regimens and explains current strategies for devising treatment plans for patients with relapsed/refractory multiple myeloma.

To download the accompanying e-Transcript for reference purposes only click here

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Amgen Inc.
View Only, CE ExpiredView Only, No Credit
 
Response Assessment in MM: Is Achieving Response Deeper than CR/sCR Important?
Response Assessment in MM: Is Achieving Response Deeper than CR/sCR Important?
CME, CPE
Ola Landgren, MD, PhD
Release Date: May 26, 2016
Expiration Date: May 26, 2017

This activity will focus on minimal residual disease (MRD), and on both how and why clinicians should assess for MRD in their patients with multiple myeloma. Data will be presented demonstrating the correlation between improved prognosis and achieving a response deeper than a complete response (CR) or stringent complete response (sCR). Join Dr. Ola Landgren, Professor of Medicine and Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering Cancer Center, as he discusses the types of tests required for accurate response assessment, the correlation between MRD and clinical outcomes, and the future implications of MRD testing on treatment strategies for patients with multiple myeloma.

To download the accompanying e-Transcript for reference purposes only click here

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
The R-ISS in Clinical Practice: A Hands-On Guide
The R-ISS in Clinical Practice: A Hands-On Guide
CME, CPE
Sagar Lonial, MD
Release Date: April 28, 2016
Expiration Date: April 28, 2017

The Revised International Staging System (R-ISS) for multiple myeloma represents a new step forward in risk stratification and prognostication for clinicians who treat patients with this disease. Using the R-ISS, clinicians will be better prepared to identify each patient’s individual risk of disease progression, and to develop therapies based specifically on that risk. In this focused activity, Dr. Sagar Lonial discusses how precision medicine is evolving for multiple myeloma, and how clinicians should apply the new standards for risk stratification and the R-ISS in their clinical practice.

To download the accompanying e-Transcript for reference purposes only click here

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
View Only, CE ExpiredView Only, No Credit
 
The Art and Science of Sequencing in Multiple Myeloma
The Art and Science of Sequencing in Multiple Myeloma
CME, CPE
Noopur Raje, MD
Release Date: March 31, 2016
Expiration Date: March 31, 2017

Join world-leading expert and Managing Myeloma faculty member Noopur Raje, MD, in a discussion focusing on the most appropriate and effective sequencing of recently approved agents for multiple myeloma across the disease life cycle.

This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Updated Diagnostic Criteria in Multiple Myeloma: The Impact on Your Clinical Practice
Updated Diagnostic Criteria in Multiple Myeloma: The Impact on Your Clinical Practice
CME, CPE
Sergio A. Giralt, MD, FACP
Release Date: February 25, 2016
Expiration Date: February 25, 2017

In 2014, the IMWG updated its criteria for the diagnosis of multiple myeloma, focusing on those diagnostic variables that determine when treatment should be initiated in the individual patient. The goal of the improved diagnostic criteria is to identify patients who will benefit from treatment prior to the emergence of CRAB symptoms, which are associated with end organ damage and poor prognosis. In this focused video, Dr. Sergio Giralt reviews the new criteria, including the roles of biomarkers of malignancy and myeloma defining events, and addresses how these new approaches to diagnosis are best applied in clinical practice.

This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
The Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management
The Importance of Establishing Baseline Disease Characteristics in Myeloma Diagnosis and Management
CME, CPE
Kenneth C. Anderson, MD, and Brian G.M. Durie, MD
Release Date: November 11, 2015
Expiration Date: November 11, 2016

Reviewed: January 17, 2017 for clinical relevance; CE is expired.

Join our world-leading Managing Myeloma team expert faculty members, Dr. Kenneth Anderson, chair of the NCCN Committee for Multiple Myeloma, and Dr. Brian G.M. Durie, chairman of the International Myeloma Foundation (IMF) Board and International Myeloma Working Group (IMWG), in a discussion regarding the importance of establishing baseline disease characteristics in myeloma diagnosis and management.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation
View Only, CE Expired
 
Advances in Consolidation, Stem Cell Collection, and Transplantation
Advances in Consolidation, Stem Cell Collection, and Transplantation
CME, CPE, CNE
Sergio Giralt, MD, and Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®
Release Date: March 15, 2013
Expiration Date: March 15, 2014

Reviewed: January 17, 2017 for clinical relevance; CE is expired.

Sergio Giralt, MD, and Beth Faiman, PhDc, RN, MSN, APRN-BC, AOCN®, navigate the management decision process for transplant-eligible patients, including tailoring treatment planning, establishing treatment goals, primary therapy choices, and addressing patient concerns as to whether autologous stem cell transplant is a necessity.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
View Only, CE Expired